^
    1m
    SGN35-027: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=255, Terminated, Seagen Inc. | Trial completion date: Jun 2026 --> Aug 2024 | Active, not recruiting --> Terminated; The study was prematurely discontinued as the sponsor believes the data collected is enough to show the safety and efficacy of the combinations studied in all cohorts. The decision was not based on any safety and/or efficacy concerns.
    Trial completion date • Trial termination
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    1m
    Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Neulasta (pegfilgrastim) • captisol-enabled melphalan
    2ms
    Study on the Efficacy and Safety of Pegfilgrastim in Primary Prevention of Chemotherapy-induced Neutropenia in Non-Hodgkin Lymphoma (ChiCTR2400087519)
    P=N/A, N=50, Not yet recruiting, Anqing Municipal Hospital; Anqing Municipal Hospital
    New trial
    |
    Neulasta (pegfilgrastim)
    2ms
    Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2; N=31; Not yet recruiting; Sponsor:Medical College of Wisconsin
    New P2 trial
    |
    clonoSEQ
    |
    doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    St. Jude ELIOT: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Oct 2024 --> Mar 2025
    Trial completion date • Combination therapy
    |
    gemcitabine • cyclophosphamide • prexasertib (ACR-368) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov)
    P2/3, N=600, Recruiting, Sutro Biopharma, Inc. | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Sep 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    3ms
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Centre Leon Berard | Trial completion date: Apr 2024 --> Sep 2025 | Trial primary completion date: Apr 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    3ms
    HO170DLBCL: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (clinicaltrials.gov)
    P3, N=324, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Neulasta (pegfilgrastim) • dexrazoxane
    3ms
    CRAFT: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (clinicaltrials.gov)
    P2, N=52, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • Rozlytrek (entrectinib) • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. (PubMed, Bladder Cancer)
    SBC is a chemosensitive subtype, with ypCR rate similar to urothelial bladder cancer following CGD neoadjuvant therapy. Whole transcriptome tissue analyses demonstrate increased expression of immune checkpoint and T-cell genes with therapeutic implications.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    cisplatin • gemcitabine • docetaxel • Neulasta (pegfilgrastim)
    4ms
    Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    carboplatin • Rozlytrek (entrectinib) • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    4ms
    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P1/2, N=4, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4
    Enrollment closed • Enrollment change
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    4ms
    Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jun 2024 --> Jun 2025
    Trial completion date
    |
    mitomycin • Neulasta (pegfilgrastim)
    4ms
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients (clinicaltrials.gov)
    P3, N=99, Recruiting, The Affiliated People's Hospital of Ningbo University
    New P3 trial
    |
    CD34 (CD34 molecule)
    |
    cytarabine • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim)
    4ms
    Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    4ms
    Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma (ChiCTR2400086421)
    P=N/A, N=87, Recruiting, The Affiliated People's Hospital of Ningbo University; The Affiliated People's Hospital of Ningbo University
    New trial
    |
    CD34 (CD34 molecule)
    |
    cytarabine • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim)
    4ms
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov)
    P3, N=1174, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Sep 2025 --> Mar 2024
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    5ms
    A case of triple negative breast cancer with cold agglutinin disease and difficulty in perioperative drug therapy (JBCS 2024)
    After that, because it was difficult to obtain intravenous drip infusion, a CV port was placed in the right subclavian vein, and docetaxel therapy was initiated...In the fourth course, perhaps because G-Lasta was administered, no FN was observed, but anemia with Hb of 5.0 was observed and a blood transfusion was required...In this case, the patient had triple-negative breast cancer with cold agglutinin disease, but during postoperative chemotherapy, she developed FN and severe anemia, making treatment difficult. It seems important to educate patients about infection control and to visit a hospital when they experience symptoms of anemia
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    BRACAnalysis CDx™
    |
    docetaxel • Neulasta (pegfilgrastim)
    5ms
    Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
    Enrollment closed • Surgery
    |
    Keytruda (pembrolizumab) • cisplatin • doxorubicin hydrochloride • methotrexate • daunorubicin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • methotrexate IV
    6ms
    Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=244, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • prednisolone
    6ms
    Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2023
    Trial completion • Trial completion date • Combination therapy
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • carfilzomib • Neulasta (pegfilgrastim)
    6ms
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    6ms
    Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (clinicaltrials.gov)
    P3, N=510, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    docetaxel • Koselugo (selumetinib) • Neulasta (pegfilgrastim)
    6ms
    Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov)
    P1, N=14, Terminated, Monopar Therapeutics | N=21 --> 14 | Trial completion date: Jun 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2023; lack of timely enrollment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    Neulasta (pegfilgrastim) • camsirubicin (MNPR-201)
    6ms
    RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=1202, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2024
    Trial completion • Trial completion date • FDG PET • Metastases
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • prednisolone
    7ms
    SWOG S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=995, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2032 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    7ms
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov)
    P2/3, N=600, Recruiting, Sutro Biopharma, Inc. | Phase classification: P2 --> P2/3 | N=140 --> 600
    Phase classification • Enrollment change
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    8ms
    St. Jude ELIOT: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, St. Jude Children's Research Hospital
    Trial completion date • Combination therapy
    |
    gemcitabine • cyclophosphamide • prexasertib (ACR-368) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    8ms
    Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery • Metastases
    |
    Avastin (bevacizumab) • cisplatin • docetaxel • etoposide IV • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    8ms
    Timing of Administration of Pegfilgrastim and Prophylaxis for Febrile Neutropenia for Patients with Early Breast Cancer Receiving Chemotherapy (PubMed, Gan To Kagaku Ryoho)
    Regarding neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer, taxanes and trastuzumab with the addition of pertuzumab have shown higher pathological complete response rates and elevated incidences of FN...The RDI of all regimens was 99.7%. Although there were some differences in chemotherapy regimens, an earlier timing of PEG prophylaxis(especially 24-48 hours from chemotherapy completion)has been shown to reduce the incidence of FN and increase the RDI.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Neulasta (pegfilgrastim)
    9ms
    EMEG-ECDD: Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Centre Georges Francois Leclerc | Trial completion date: Apr 2024 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Granocyte (lenograstim) • Neupogen (filgrastim)
    9ms
    Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study. (PubMed, Br J Haematol)
    The duration of neutrophil and platelet engraftment was 11 days. In conclusion, these results suggest that the EAP mobilization regimen might be a promising option for poorly mobilizing patients with MM or lymphoma.
    Journal
    |
    CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • Neulasta (pegfilgrastim)
    9ms
    Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov)
    P1, N=21, Recruiting, Monopar Therapeutics | Phase classification: P1b --> P1 | Trial primary completion date: Jun 2023 --> Jun 2025
    Phase classification • Trial primary completion date • Metastases
    |
    Neulasta (pegfilgrastim) • camsirubicin (MNPR-201)
    9ms
    NEUTHREE: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (clinicaltrials.gov)
    P4, N=100, Recruiting, Eunseong Medical Foundation Good GANG-AN HOSPITAL | Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Jul 2024 --> Jan 2025
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Neulasta (pegfilgrastim) • Rolvedon (eflapegrastim-xnst)
    9ms
    NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    ALK fusion • ALK mutation • ALK translocation • ALK amplification
    |
    Lorbrena (lorlatinib) • cyclophosphamide • topotecan • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    9ms
    Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Jun 2024
    Trial completion date
    |
    mitomycin • Neulasta (pegfilgrastim)
    10ms
    NCI-2018-01186: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    11ms
    Split-Dose R-CHOP for Older Adults With DLBCL (clinicaltrials.gov)
    P2, N=26, Recruiting, University of Wisconsin, Madison
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    11ms
    SWOG S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=995, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2032
    Trial completion date • Metastases
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    11ms
    SWOG S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=995, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Jun 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    12ms
    NCI-2018-01119: Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=116, Recruiting, M.D. Anderson Cancer Center | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    Venclexta (venetoclax) • cytarabine • idarubicin hydrochloride • fludarabine IV • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    12ms
    EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM (SIE 2023)
    Similar results were obtained performing two separate sub-analysis only for lymphoma or myeloma patients. From our data biosimilar Pegfilgrastim seems to be substantially equivalent in terms of efficacy to the originator one and superior than Lenograstim and biosimilar Filgrastim in terms of hematologic recovery, when used in this setting.
    Clinical
    |
    CD34 (CD34 molecule)
    |
    Neulasta (pegfilgrastim)